Melanoma, version 4.2014: Featured updates to the NCCN guidelines

Daniel G. Coit, John A. Thompson, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson, Gregory A. Daniels, Adil Daud, Dominick J DiMaio, Martin D. Fleming, Rene Gonzalez, Valerie Guild, Allan C. Halpern, F. Stephen Hodi, Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Mary C. Martini, Anthony J. OlszanskiMerrick I. Ross, April Salama, Susan M. Swetter, Kenneth K. Tanabe, Vijay Trisal, Marshall M. Urist, Nicole R. McMillian, Maria Ho

Research output: Contribution to journalReview article

52 Citations (Scopus)

Abstract

The NCCN Guidelines for Melanoma provide multidisciplinary recommendations for the management of patients with melanoma. These NCCN Guidelines Insights highlight notable recent updates. Dabrafenib and trametinib, either as monotherapy (category 1) or combination therapy, have been added as systemic options for patients with unresectable metastatic melanoma harboring BRAF V600 mutations. Controversy continues regarding the value of adjuvant radiation for patients at high risk of nodal relapse. This is reflected in the category 2B designation to consider adjuvant radiation following lymphadenectomy for stage III melanoma with clinically positive nodes or recurrent disease.

Original languageEnglish (US)
Pages (from-to)621-629
Number of pages9
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume12
Issue number5
DOIs
StatePublished - Jan 1 2014

Fingerprint

Melanoma
Guidelines
Radiation
Lymph Node Excision
Recurrence
Mutation
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Coit, D. G., Thompson, J. A., Andtbacka, R., Anker, C. J., Bichakjian, C. K., Carson, W. E., ... Ho, M. (2014). Melanoma, version 4.2014: Featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 12(5), 621-629. https://doi.org/10.6004/jnccn.2014.0066

Melanoma, version 4.2014 : Featured updates to the NCCN guidelines. / Coit, Daniel G.; Thompson, John A.; Andtbacka, Robert; Anker, Christopher J.; Bichakjian, Christopher K.; Carson, William E.; Daniels, Gregory A.; Daud, Adil; DiMaio, Dominick J; Fleming, Martin D.; Gonzalez, Rene; Guild, Valerie; Halpern, Allan C.; Hodi, F. Stephen; Kelley, Mark C.; Khushalani, Nikhil I.; Kudchadkar, Ragini R.; Lange, Julie R.; Martini, Mary C.; Olszanski, Anthony J.; Ross, Merrick I.; Salama, April; Swetter, Susan M.; Tanabe, Kenneth K.; Trisal, Vijay; Urist, Marshall M.; McMillian, Nicole R.; Ho, Maria.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 12, No. 5, 01.01.2014, p. 621-629.

Research output: Contribution to journalReview article

Coit, DG, Thompson, JA, Andtbacka, R, Anker, CJ, Bichakjian, CK, Carson, WE, Daniels, GA, Daud, A, DiMaio, DJ, Fleming, MD, Gonzalez, R, Guild, V, Halpern, AC, Hodi, FS, Kelley, MC, Khushalani, NI, Kudchadkar, RR, Lange, JR, Martini, MC, Olszanski, AJ, Ross, MI, Salama, A, Swetter, SM, Tanabe, KK, Trisal, V, Urist, MM, McMillian, NR & Ho, M 2014, 'Melanoma, version 4.2014: Featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 12, no. 5, pp. 621-629. https://doi.org/10.6004/jnccn.2014.0066
Coit, Daniel G. ; Thompson, John A. ; Andtbacka, Robert ; Anker, Christopher J. ; Bichakjian, Christopher K. ; Carson, William E. ; Daniels, Gregory A. ; Daud, Adil ; DiMaio, Dominick J ; Fleming, Martin D. ; Gonzalez, Rene ; Guild, Valerie ; Halpern, Allan C. ; Hodi, F. Stephen ; Kelley, Mark C. ; Khushalani, Nikhil I. ; Kudchadkar, Ragini R. ; Lange, Julie R. ; Martini, Mary C. ; Olszanski, Anthony J. ; Ross, Merrick I. ; Salama, April ; Swetter, Susan M. ; Tanabe, Kenneth K. ; Trisal, Vijay ; Urist, Marshall M. ; McMillian, Nicole R. ; Ho, Maria. / Melanoma, version 4.2014 : Featured updates to the NCCN guidelines. In: JNCCN Journal of the National Comprehensive Cancer Network. 2014 ; Vol. 12, No. 5. pp. 621-629.
@article{6db1cc7fb1494483a845729176c16f76,
title = "Melanoma, version 4.2014: Featured updates to the NCCN guidelines",
abstract = "The NCCN Guidelines for Melanoma provide multidisciplinary recommendations for the management of patients with melanoma. These NCCN Guidelines Insights highlight notable recent updates. Dabrafenib and trametinib, either as monotherapy (category 1) or combination therapy, have been added as systemic options for patients with unresectable metastatic melanoma harboring BRAF V600 mutations. Controversy continues regarding the value of adjuvant radiation for patients at high risk of nodal relapse. This is reflected in the category 2B designation to consider adjuvant radiation following lymphadenectomy for stage III melanoma with clinically positive nodes or recurrent disease.",
author = "Coit, {Daniel G.} and Thompson, {John A.} and Robert Andtbacka and Anker, {Christopher J.} and Bichakjian, {Christopher K.} and Carson, {William E.} and Daniels, {Gregory A.} and Adil Daud and DiMaio, {Dominick J} and Fleming, {Martin D.} and Rene Gonzalez and Valerie Guild and Halpern, {Allan C.} and Hodi, {F. Stephen} and Kelley, {Mark C.} and Khushalani, {Nikhil I.} and Kudchadkar, {Ragini R.} and Lange, {Julie R.} and Martini, {Mary C.} and Olszanski, {Anthony J.} and Ross, {Merrick I.} and April Salama and Swetter, {Susan M.} and Tanabe, {Kenneth K.} and Vijay Trisal and Urist, {Marshall M.} and McMillian, {Nicole R.} and Maria Ho",
year = "2014",
month = "1",
day = "1",
doi = "10.6004/jnccn.2014.0066",
language = "English (US)",
volume = "12",
pages = "621--629",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "5",

}

TY - JOUR

T1 - Melanoma, version 4.2014

T2 - Featured updates to the NCCN guidelines

AU - Coit, Daniel G.

AU - Thompson, John A.

AU - Andtbacka, Robert

AU - Anker, Christopher J.

AU - Bichakjian, Christopher K.

AU - Carson, William E.

AU - Daniels, Gregory A.

AU - Daud, Adil

AU - DiMaio, Dominick J

AU - Fleming, Martin D.

AU - Gonzalez, Rene

AU - Guild, Valerie

AU - Halpern, Allan C.

AU - Hodi, F. Stephen

AU - Kelley, Mark C.

AU - Khushalani, Nikhil I.

AU - Kudchadkar, Ragini R.

AU - Lange, Julie R.

AU - Martini, Mary C.

AU - Olszanski, Anthony J.

AU - Ross, Merrick I.

AU - Salama, April

AU - Swetter, Susan M.

AU - Tanabe, Kenneth K.

AU - Trisal, Vijay

AU - Urist, Marshall M.

AU - McMillian, Nicole R.

AU - Ho, Maria

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The NCCN Guidelines for Melanoma provide multidisciplinary recommendations for the management of patients with melanoma. These NCCN Guidelines Insights highlight notable recent updates. Dabrafenib and trametinib, either as monotherapy (category 1) or combination therapy, have been added as systemic options for patients with unresectable metastatic melanoma harboring BRAF V600 mutations. Controversy continues regarding the value of adjuvant radiation for patients at high risk of nodal relapse. This is reflected in the category 2B designation to consider adjuvant radiation following lymphadenectomy for stage III melanoma with clinically positive nodes or recurrent disease.

AB - The NCCN Guidelines for Melanoma provide multidisciplinary recommendations for the management of patients with melanoma. These NCCN Guidelines Insights highlight notable recent updates. Dabrafenib and trametinib, either as monotherapy (category 1) or combination therapy, have been added as systemic options for patients with unresectable metastatic melanoma harboring BRAF V600 mutations. Controversy continues regarding the value of adjuvant radiation for patients at high risk of nodal relapse. This is reflected in the category 2B designation to consider adjuvant radiation following lymphadenectomy for stage III melanoma with clinically positive nodes or recurrent disease.

UR - http://www.scopus.com/inward/record.url?scp=84900423555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900423555&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2014.0066

DO - 10.6004/jnccn.2014.0066

M3 - Review article

C2 - 24812131

AN - SCOPUS:84900423555

VL - 12

SP - 621

EP - 629

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 5

ER -